Nanoveu’s (ASX:NVU) antiviral phone protection gains TGA approval

• Nanoveu’s (NVU) antiviral phone protection technology has been approved by the Australian Therapeutics Goods Administration
• The technology has received Class I Medical Device status which means it has a low to moderate risk
• This successful registration means the technology is now listed on the Australian Register of Therapeutics Goods (ARTG) and can now be sold within Australia
• Nanoveu’s technology contains copper oxide nanoparticles which damage the protective covering of a virus and eventually causing them to die
• The company will now focus its regulatory efforts towards a submission to the United States Environmental Protection Agency
• Nanoveu is down a slight three per cent and shares are trading for 9.7 cents each just before market close

Nanoveu’s (NVU) antiviral phone protection technology has been approved by the Australian Therapeutics Goods Administration (TGA).

The technology has received Class I Medical Device status which means it has a low to moderate risk. Equipment with this status include surgical retractors and tongue depressors.

This successful registration means the technology is now listed on the Australian Register of Therapeutics Goods (ARTG) and can be sold within Australia.

The registration follows the successful testing of the technology against a wide range of coronaviruses.

Nanoveu’s technology contains copper oxide nanoparticles which damage the protective covering of a virus and eventually causing them to die.

“Nanoveu continues to work to bring antiviral phone protection products to market and it is pleasing to see this regulatory hurdle surpassed,” Executive Chairman and CEO Alfred Chong commented.

“To date we have received a number of highly positive results right across our regulatory, production and testing activities,” he said.

“The addition of our technology to the ARTG is an important step in the commercialisation process and we continue to anticipate the launch in late Q2 2020 or early Q3 2020,” he added.

Nanoveu will now focus its regulatory efforts towards a submission to the United States Environmental Protection Agency (EPA).

The EPA is tasked with protecting both human and environmental health, and creating standards and laws to promote the health of individuals and the environment.

Specialised EPA consultants have been appointed to assist with this process.

Nanoveu is down a slight three per cent and shares are trading for 9.7 cents each just before market close.